On December 16, 2023, the "2023 CHIP TOP 10 Seeds List" was released at the "Qike 50 Annual Conference" held in Shanghai Tower, Lujiazui Financial Zone, Shanghai. Dr. Liming Shao, Chairman of the CHIP Pharmaceutical Special Committee, Director of the Shanghai Drug R&D Collaborative Innovation Center, and Prof. of the School of Pharmacy at Fudan University, released the "2023 Biopharmaceutical Innovation CHIP Top 10 Seed list” and presented the awards to the biotech companies that won the honor. Dr. Chao Tu, Co-Founder and CEO of Biomissile, attended the conference and accepted the award.
Dr. Tu stated: “As a clinical stage biotech company focusing on developing innovative biological drugs, Biomissile has more than 10 candidates under development with two leading projects in Phase I and II respectively, and the third one in IND filing stage. In the last several months of intense defenses in the preliminary, secondary, and final rounds, more than 100 experts from CHIP expert committee and the organizing committee evaluated various companies from multiple dimensions including technology innovation, business model possibility, market developability, team capabilities, financial return rate etc, Biomissile ultimately stood out and was selected as one of the top 10 CHIP seeds in 2023. We are very grateful for the recognitions from CHIP experts and VCs.”
About CHIP (China Healthcare Innovation Platform) and CHIP seed list
The China Healthcare Innovation Platform (CHIP) was jointly initiated in 2014 by Mr. Jiangnan Cai, a renowned expert in Chinese health economics and policy, and the leaders in the healthcare industry. It mainly focuses on China local business model innovation, management innovation, institutional innovation, and major technological innovation, aiming to enhance the positive value and social recognition of innovation by connecting industry, academia and government investment, improve and enhance the interests of stakeholders and the entire society, thereby obtaining excellent economic and social benefits, leading the innovation environment of the healthcare industry, and promoting the development of the healthcare industry in the reforming healthcare system.
To encourage and explore the most promising early-stage innovative projects in Chinese healthcare industry, the CHIP Expert Committee and Organizing Committee launched the "CHIP Seeds List".
The joint publishers of the 2023 CHIP Seed List include: Shanghai Minhang Chunshen Pyramid Talent College, Shanghai South Science and Technology Innovation Training Base, Shanghai Wujiaochang Innovation and Entrepreneurship College, New Hushang, China Pharmaceutical Industry Information Center, Beijing Medical Robot Industry Entrepreneurship Center, Shanghai Free Trade Zone Simbay Park, Shanghai Juke Biotech Park, Takeda China, Guangzhou Jiutai Pharmaceutical Technology Co., Ltd., Aozida Medical Device Industry Group, Ruizhengfu, Jianyi Capital, Warburg Princus, Lilly Asia Ventures, Step Holdings, Haoyue Capital, Probing VC, Trifecta Consulting, China Innovation and Entrepreneurship Competition, E-Doctor, Bio Club, Cas Club, Sina Health, China Enterprise News, Yunque Yi, 001Yixue, Yixuejie, and Vistamed.
About Biomissile
Biomissile Pharmaceuticals Co., Ltd. is a clinical stage biotech company focusing on developing fully human domain antibody (UDABTM) and multi-specific antibody (UDAB-MTM) to fight a range of diseases with global unmet medical needs. We aim to become a premium innovative biopharmaceutical company based on our unique platform technologies, strong pipeline, and outstanding team. We have established five proprietary platforms for rapid antibody discovery and optimization, including the leading platforms for fully human domain antibody (UDATM) and multi-specific antibody (UDAB-MTM), as well as the largest libraries of phage, yeast and mammalian cell display platforms. Relying on the strong platform technologies, the company has more than 10 innovative candidates under development in a short period of time, including several First-in-Class domain antibodies (VH) and multi-specific UDAB-MTM molecules to specifically activate immune cells in the tumor microenvironment (TME). So far, two leading projects are in clinical stage (in Phase I &II) and the third one is in IND filing stage.
Biomissile has successfully assembled a global, seasoned leadership team in antibody discovery, manufacturing, clinical, registration and business development. The core team members are composed of experts with an average of more than 20 years’ experience in biological R&D and commercialization. The company has a state-of-the-art R&D lab in Shanghai, a future GMP facility in Suzhou, and a global regulatory & BD team in Boston, USA. We are committed to the disruptive innovation of biological drugs to benefit patients worldwide.
Link to the news in Chinese:
https://mp.weixin.qq.com/s/ICv8dhsNBI5oSYKVL5btjg
BD: bd@biomissile.com
HR: hr@biomissile.com
Website: www.biomissile.com